Recent non-hydroxamate matrix metalloproteinase inhibitors

被引:64
作者
Breuer, E
Frant, J
Reich, R
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel
关键词
allosteric; antiangiogenic; anti-invasive; arthritis; atherosclerosis; cancer; cartilage degradation; chelator; chronic obstructive pulmonary disease (COPD); collagenase; coronary artery disease; extracellular matrix (ECM); hydroxamic acid; inflammation; inhibitor; metastasis; matrix metalloproteinase (MMP); MMP inhibitor (MMPI); myocardial infarction; osteoarthritis; periodontal disease; remodelling; rheumatoid arthritis; X-ray crystallography;
D O I
10.1517/13543776.15.3.253
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that have the capacity to degrade all elements of the extracellular matrix (ECM) and are required for homeostatic maintenance of the ECM. Interest in MMPs arose from the accumulating evidence implying that over-activity of MMPs plays a role in mediating or accompanying a diverse array of pathologies. Because of this, there has been an ongoing, and alas unsuccessful, effort for nearly two decades to develop clinically applicable MMP inhibitors (MMPIs) as drugs. The largest family of the inhibitor candidates that failed in clinical trials is that of hydroxamic acids. This review i) attempts to rationalise the failure of hydroxamates as MMPIs, ii) critically reviews publications and patents of the last few years, which report new non-hydroxamate based MMPIs, and iii) summarises factors that are considered important for success in developing clinically useful MMPIs.
引用
收藏
页码:253 / 269
页数:17
相关论文
共 50 条
[41]   Matrix metalloproteinase inhibitors as anticancer agents [J].
Konstantinopoulos, Panagiotis A. ;
Karamouzis, Michalis V. ;
Papatsoris, Athanasios G. ;
Papavassiliou, Athanasios G. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (6-7) :1156-1168
[42]   Matrix metalloproteinase inhibitors in the treatment of cancer [J].
Brown, PD .
MEDICAL ONCOLOGY, 1997, 14 (01) :1-10
[43]   Matrix metalloproteinase inhibitors in the treatment of cancer [J].
Peter D. Brown .
Medical Oncology, 1997, 14 :1-10
[44]   Progress in the design of matrix metalloproteinase inhibitors [J].
Cheng, F ;
Liu, H ;
Luo, XM ;
Jiang, HL ;
Shen, JK ;
Chen, KX ;
Ji, RY .
PROGRESS IN CHEMISTRY, 2001, 13 (04) :283-293
[45]   Selective Matrix Metalloproteinase Inhibitors for Cancer [J].
Li, Nian-Guang ;
Shi, Zhi-Hao ;
Tang, Yu-Ping ;
Duan, Jin-Ao .
CURRENT MEDICINAL CHEMISTRY, 2009, 16 (29) :3805-3827
[46]   Clinical Investigation of Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases, and Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Complexes and Their Networks in Apical Periodontitis [J].
Martinho, Frederico C. ;
Teixeira, Flavia F. C. ;
Cardoso, Flavia G. R. ;
Ferreira, Nadia S. ;
Nascimento, Gustavo G. ;
Carvalho, Claudio A. T. ;
Valera, Marcia C. .
JOURNAL OF ENDODONTICS, 2016, 42 (07) :1082-1088
[47]   Repurposing of DrugBank molecules as dual non-hydroxamate HDAC8 and HDAC2 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics studies [J].
Sarkar, Kakali ;
Debnath, Sudhan ;
Ghosh, Rajat ;
Choudhury, Deijy ;
Chakraborty, Kanak ;
Saha, Partha ;
Singha, Achinta ;
Nandi, Addrita ;
Goswami, Bidhan ;
Ghosh, Arabinda ;
Sil, Samir Kumar .
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,
[48]   Matrix metalloproteinase inhibitors - an emphasis on gastrointestinal malignancies [J].
Chau, I ;
Rigg, A ;
Cunningham, D .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) :151-176
[50]   Design and Structural Evolution of Matrix Metalloproteinase Inhibitors [J].
Fischer, Thomas ;
Senn, Nicole ;
Riedl, Rainer .
CHEMISTRY-A EUROPEAN JOURNAL, 2019, 25 (34) :7960-7980